The purpose of this study is to assess the efficacy of omarigliptin 25 mg weekly (as monotherapy) compared with sitagliptin 50 mg daily and placebo, and the long term safety (up to 52 weeks) of omarigliptin 25 mg weekly. The primary hypotheses are that after 24 weeks: 1) Omarigliptin 25 mg weekly provides a greater reduction from baseline in glycosylated hemoglobin (HbA1c) compared with placebo, and 2) The mean change from baseline in HbA1c in participants treated with omarigliptin 25 mg weekly is non-inferior compared with that in participants treated with sitagliptin 50 mg daily.
Age range
20 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change From Baseline for Hemoglobin A1c (HbA1c) at Week 24
Timeframe: Baseline and Week 24
Percentage of Participants Who Experienced at Least One Adverse Event During Phase A
Timeframe: Up to 24 weeks
Percentage of Participants Who Experienced at Least One Adverse Event During the Overall Study
Timeframe: Up to 52 weeks
Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During Phase A
Timeframe: Up to 24 weeks
Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study
Timeframe: Up to 52 weeks